{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:45:26Z","timestamp":1790829926956,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":5562,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1093\/annonc\/mdh403","type":"journal-article","created":{"date-parts":[[2004,9,14]],"date-time":"2004-09-14T19:28:40Z","timestamp":1095190120000},"page":"1481-1483","source":"Crossref","is-referenced-by-count":141,"title":["Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia"],"prefix":"10.1016","volume":"15","author":[{"given":"S.P.","family":"Treon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Branagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Tournhilac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh403_bb0010","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstr\u00f6m's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstr\u00f6m's macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh403_bb0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V49.4.507.507","article-title":"Blood viscosity in Waldenstrom's macroglobulinemia","volume":"49","author":"MacKenzie","year":"1977","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh403_bb0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/sonc.2003.50047","article-title":"Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations","volume":"30","author":"Treon","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh403_bb0025","first-page":"97","article-title":"Treatment of plasma cell dyscrasias by antibody immunotherapy","volume":"26","author":"Treon","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh403_bb0030","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1023\/A:1008350208019","article-title":"Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity","volume":"10","author":"Byrd","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh403_bb0035","first-page":"125","article-title":"Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia","volume":"94","author":"Weber","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh403_bb0040","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002371-200105000-00012","article-title":"CD20 directed serotherapy induces responses and facilitates hematological recovery in patients with Waldenstrom's macroglobulinemia","volume":"24","author":"Treon","year":"2001","journal-title":"J Immunotherapy"},{"key":"10.1093\/annonc\/mdh403_bb0045","first-page":"102","article-title":"Rituximab for Waldenstrom's macroglobulinemia: an ECOG phase II study for untreated and previously treated patients","volume":"148a","author":"Gert","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh403_bb0050","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstrom's macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh403_bb0055","first-page":"211a","article-title":"Combination therapy with rituximab and fludarabine is highly active in Waldenstrom's macroglobulinemia","volume":"100","author":"Treon","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh403_bb0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/sonc.2003.50070","article-title":"Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia","volume":"30","author":"Weber","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh403_bb0065","first-page":"85","article-title":"Rituximab as single agent and in combination with interferon-a-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas: A randomized phase II study","volume":"13","author":"Kimby","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh403_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/sonc.2003.50039","article-title":"Treatment Recommendations in Waldenstrom's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia","volume":"30","author":"Gertz","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh403_bb0075","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/eji.1830230330","article-title":"CD20 monoclonal antibodies down-regulate IgM at the surface of B-cells","volume":"23","author":"Bourget","year":"1993","journal-title":"Eur J Immunol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419510572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419510572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/10\/1481\/407798\/mdh403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T18:20:27Z","timestamp":1582222827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419510572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S0923753419510572"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh403","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}